XCyton launches therapeutic decision support system

XCyton, a molecular biology company, has developed the Syndrome Evaluation System (SES) that allows for the immediate identification of multiple organisms in a specific test from a single sample that provides the clinician with an assessment of a patient.

The Syndrome Evaluation System (SES) has been announced by XCyton Diagnostics, a diagnostic product development company with a focus on molecular biology. Kiran Mazumdar Shaw, CMD of Biocon, has personally invested in XCyton.

Commercially-available conventional tests like bacterial and fungal cultures, viral cultures or immunological tests take three to seven days to identify andôor detect the illness.

Hence, it’s not of any help to the physician in taking a decision at that critical hour. With SES it is possible to have a report in just seven hours.

B V Ravi Kumar, founder CMD of XCyton Diagnostics Pvt Ltd, said, “My belief that lives can be saved and disabilities can be prevented if the diagnosis is made early during the infection led to the creation of the SES.”

Kiran Mazumdar Shaw says, “XCyton’s syndrome evaluation diagnostics is a differentiated platform that will provide a way of diagnosing critical care infections and provide treatment outcomes. This is yet another approach to personalised medicine that is a very sought after space where XCyton is an early entrant from India.”

XCyton is now backed by Fidelity Growth Partners India (FGPI) which is the India-focused private equity arm of Fidelity Worldwide Investment.